Register Login

BRIDGEBIO PHARMA, INC. (BBIO)

Director Valantine Hannah 🟡 adjusted position in 4.3K shares (2 derivative) of BridgeBio Pharma, Inc. (BBIO) at $68.92 Transaction Date: Jun 22, 2026 | Filing ID: 000635

Full text
Register to leave comments
  • News bot June 24, 2026, 10:07 p.m.

    🔍 Valantine Hannah (Director)

    Company: BridgeBio Pharma, Inc. (BBIO)

    Report Date: 2026-06-22

    Transaction Summary:

    • Total transactions: 7
    • Derivative instruments: 2
    • Holdings reported: 1
    • Total shares acquired: 12,075
    • Total shares sold: 7,812
    • Total shares held: 398

    Detailed Transactions and Holdings:

    • Acquired 3,990 shares of Common Stock (Direct)
      Date: 2026-06-22 | Code: A | equity_swap_involved: 0 | shares_owned_after: 11,455.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Acquired 2,808 shares of Common Stock at $41.73 per share (Direct)
      Date: 2026-06-22 | Code: M | equity_swap_involved: 0 | shares_owned_after: 14,263.00 | transaction_form_type: 4
    • Sold 2,808 shares of Common Stock at $68.0 per share (Direct)
      Date: 2026-06-22 | Code: S | equity_swap_involved: 0 | shares_owned_after: 11,455.00 | transaction_form_type: 4 | Footnotes: F3
    • Sold 2,196 shares of Common Stock at $68.57 per share (Direct)
      Date: 2026-06-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 9,259.00 | transaction_form_type: 4 | Footnotes: F3
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-06-22 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 398.00
    • Acquired 5,277 shares of Stock Option (Right to Buy) at $68.92 per share (Derivative)
      Date: 2026-06-22 | Code: A | Expires: 2036-06-21 | equity_swap_involved: 0 | shares_owned_after: 5,277.00 | transaction_form_type: 4 | Footnotes: F4
    • Sold 2,808 shares of Stock Option (Right to Buy) at $41.73 per share (Derivative)
      Date: 2026-06-22 | Code: M | Expires: 2035-06-19 | equity_swap_involved: 0 | shares_owned_after: 5,617.00 | transaction_form_type: 4 | Footnotes: F5

    Footnotes:

    • F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
    • F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
    • F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.
    • F4: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
    • F5: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

Search

News categories